



Effectiveness and Safety of the Telmisartan and Amlodipine Fixed-dose Combination in Managing Hypertension among Indian Patients (TACT India Study): Rationale and Study Design

Das AK et.al: J of the Association of Physicians of India; 2024;72(11):e16-e20

- TACT India is a prospective, longitudinal, multicenter, observational study that evaluates the efficacy and safety of the fixed-dose combination (FDC) of telmisartan and amlodipine in Indian patients diagnosed with hypertension.
- In a randomized, double-blind, controlled trial lasting 8 weeks with inclusion of 1,097 patients with poorly managed hypertension (DBP ≥ 90 mm Hg), comparing FDCs of telmisartan 40 or 80 mg/amlodipine 5 mg (T40/A5 or T80/A5) to amlodipine 5 mg (A5) monotherapy has shown notable results without significant adverse reactions.
- A small population cohort study of 251 stage II hypertensive patients found that an FDC of telmisartan 40 mg and amlodipine 5 mg resulted in an effective BP reduction of 23% after 8 weeks. This combination has gained significant clinical support due to the prolonged duration of action of each drug class.
- Telmisartan and amlodipine FDC belong to the preferred single-pill combination of the antihypertensive class of drugs (ARB+CCB combination) and are endorsed by major guidelines for managing hypertension

Telmisartan and amlodipine FDC belong to the preferred single-pill combination of the antihypertensive class of drugs (ARB+CCB) and are endorsed by major guidelines for managing hypertension. TACT India study shall provide larger population data on this FDC over 8 weeks study duration.

